Brainstorm Cell Therapeutics, Inc. (BCLI)
1.08
+0.05
(+4.85%)
USD |
OTCM |
Sep 11, 16:00
Brainstorm Cell Therapeutics Enterprise Value : 13.27M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 13.27M |
| September 10, 2026 | 12.72M |
| September 09, 2026 | 12.39M |
| September 08, 2026 | 12.28M |
| September 04, 2026 | 12.94M |
| September 03, 2026 | 13.16M |
| September 02, 2026 | 15.15M |
| September 01, 2026 | 14.24M |
| August 31, 2026 | 13.10M |
| August 28, 2026 | 13.75M |
| August 27, 2026 | 14.18M |
| August 26, 2026 | 14.59M |
| August 25, 2026 | 12.39M |
| August 24, 2026 | 12.39M |
| August 21, 2026 | 12.17M |
| August 20, 2026 | 13.05M |
| August 19, 2026 | 14.79M |
| August 18, 2026 | 16.91M |
| August 17, 2026 | 13.33M |
| August 14, 2026 | 12.28M |
| August 13, 2026 | 10.36M |
| August 12, 2026 | 10.92M |
| August 11, 2026 | 10.73M |
| August 10, 2026 | 10.07M |
| August 07, 2026 | 10.04M |
| Date | Value |
|---|---|
| August 06, 2026 | 10.18M |
| August 05, 2026 | 9.914M |
| August 04, 2026 | 9.876M |
| August 03, 2026 | 10.07M |
| July 31, 2026 | 11.28M |
| July 30, 2026 | 11.48M |
| July 29, 2026 | 11.23M |
| July 28, 2026 | 11.50M |
| July 27, 2026 | 11.66M |
| July 24, 2026 | 11.95M |
| July 23, 2026 | 12.39M |
| July 22, 2026 | 12.17M |
| July 21, 2026 | 11.50M |
| July 20, 2026 | 11.84M |
| July 17, 2026 | 11.24M |
| July 16, 2026 | 11.75M |
| July 15, 2026 | 12.09M |
| July 14, 2026 | 11.95M |
| July 13, 2026 | 12.89M |
| July 10, 2026 | 13.27M |
| July 09, 2026 | 13.16M |
| July 08, 2026 | 13.93M |
| July 07, 2026 | 14.96M |
| July 06, 2026 | 15.70M |
| July 02, 2026 | 17.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Summit Therapeutics, Inc. | 13.25B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 85.96M |
| Clene, Inc. | 58.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.855M |
| Total Expenses (Quarterly) | 3.855M |
| EPS Diluted (Quarterly) | -0.3494 |
| Earnings Yield | -88.34% |
| Normalized Earnings Yield | -88.33 |